Immunitybio, Inc. (ibrx) Investors: May 26, 2026

The Story

Investors who bought ImmunityBio securities between January 19, 2026 and March 24, 2026 have until May 26, 2026 to seek lead plaintiff status in a securities fraud class action, according to the notice. The case targets events during the stated class period and may affect $IBRX shareholders' legal options and near-term trading dynamics.

Why It Matters For Your Portfolio

• Deadline Risk: May 26, 2026 is the cutoff to move for lead plaintiff status, which can shape the litigation strategy and potential settlement timeline, increasing event-driven volatility for $IBRX.
• Exposure Window: The class period runs January 19 through March 24, 2026, so purchases in that window are the focus for claims and possible recovery calculations.
• Valuation Inputs: Multiple data points noted for valuation analysis include 0.62%, 0.31%, and 0.03%, which investors may use when modeling dilution, impairment, or loss scenarios.
• Portfolio Impact: Lead plaintiff selection and subsequent filings can prompt disclosure changes, legal fees, and share-price swings, which could pressure holdings tied to $IBRX.

The Trade

Who should care: current $IBRX holders, event-driven traders, and portfolio managers who track litigation risk. Watch the court docket and any lead plaintiff motions filed ahead of the May 26 deadline, plus company disclosures that reference litigation exposure. Do you qualify to participate in motions or claims? Check the filing notice and consider how potential legal outcomes affect your risk assumptions.

This coverage is informational only and not individualized investment advice.